Global Neuroscience Market, by Component (Instrument, Software, and Services), by End User (Hospital, Diagnostic Laboratories, Research Institutes, and Academic Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 27,630.13 million in 2018, and is expected to exhibit a CAGR of 3.9% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Neurological disorders are the diseases of central and peripheral nervous system. These disorders include epilepsy, Alzheimer disease and other dementias, cerebrovascular diseases including stroke, migraine, and other headache disorders, multiple sclerosis, Parkinson's disease, neuroinfections, brain tumors, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition. These diseases are also affected by various infections such as bacterial (Mycobacterial tuberculosis and Neisseria meningitides), viral (Human Immunodeficiency Virus (HIV), Enteroviruses, West Nile Virus, and Zika), fungal (Cryptococcus, and Aspergillus), and parasitic (malaria and Chagas). These pathogens has potential to affect the nervous system, which leads to neurological symptoms due to the infection itself or weaken immune response of the individuals.

Increasing incidence of neurological disorders is expected to propel growth of the market over the forecast period. For instance, according to the World Health Organization (WHO), a report published, in 2016, globally there are 7.7 million new cases of dementia every year. Moreover, Alzheimer disease-being the most common cause of dementia, contributes to 60.0-70.0% of such cases. Furthermore, according to the Mindgardens Neuroscience Network, in 2017, in Australia, the leading cause of disability is mental health and neurological disorders, which accounted for 20.5% of total Australian daily adjusted life years (DALYs).

Key players in the market are focused on launching new products, which in turn is expected to boost the market growth during the forecast period. For instance, in August 2017, GE Healthcare launched Signa Premier, a new wide bore 3.0T magnetic resonance imaging (MRI) system in the U.S. This system delivers a new level of clinical performance with additional research-focused capabilities, especially for neurology and oncology research.

Browse 23 Market Data Tables and 26 Figures spread through 165 Pages and in-depth TOC on “Neuroscience Market” - Global forecast to 2027, by Component (Instrument, Software, and Services), by End User (Hospital, Diagnostic Laboratories, Research Institutes, and Academic Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Neuroscience Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/neuroscience-market-2487

Asia Pacific is expected to offer lucrative market opportunity in the Neuroscience market over the forecast period, owing to rising incidences of CNS disorders in the region. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in 2018 reports that the burden of dementia in Japan is growing and it is expected that 1 in 5 elderly people will suffer from dementia in Japan by 2025.

Moreover, increasing patient pool of neurological disorders in this region is expected to drive growth of the market over the forecast period. For instance, according to the Mindgardens Neuroscience Network, the total prevalence of neurological disorders in 2017 in Australia were 10.6 million (43.0%) followed by mental health disorders of 4 million (16.3%), and substance disorders of 0.8 million people (3.2.0%).

Key Takeaways of the Neuroscience Market:

  • The global neuroscience market is expected to exhibit a CAGR of 3.9% over the forecast period, owing to increasing product development and product approvals that are expected to boost growth of the neuroscience market over the forecast period. For instance, in July 2019, INSIGHTEC (Israel) and GE Healthcare (U.S.) received an approval from the U.S. Food and Drug Administration (FDA) and Conformité Européenne (CE) mark for its Exablate Neuro with the SIGNA Premier MRI. The product offers focused ultrasound treatment options for neurology.
  • Among component, instrument segment held dominant position in the neuroscience market in 2018, owing to better results in with less time which is leading to product development and launches. For instance, in September 2015, Codman Neuro (Division of DePuy Synthes) launched CODMAN CERTAS plus programmable valve. The product is an MRI-resistant programmable valve with eight different pressure settings, which supports to treat hydrocephalus.
  • Among end user, hospitals segment held dominant position in the neuroscience market in 2018, owing to rising number of population with neurological disorders. For instance, according to the Mindgardens Neuroscience Network, globally in 2017 the total burden of neurological, mental health, and substance abuse disorders accounted for 11.1% of the total burden of disease.
  • Companies operating in the global neuroscience market include Alpha Omega, Inc., GE Healthcare, Axion Biosystems, Inc., Siemens Healthineers, Scientifica Ltd., Blackrock Microsystems LLC, Femtonics Ltd., LaVision Biotec GmbH, Intan Technologies, NeuroNexus Technologies, Inc., Newport Corporation, Neuralynx Inc., Plexon Inc., Mediso Medical Imaging Systems, Noldus Information Technology, Sutter Instrument Corporation, Thomas Recording GmbH, and Trifoil Imaging Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: